ELCC 2019: Patient-Reported Outcomes With Durvalumab in NSCLC
Posted: Friday, May 3, 2019
PD-L1 expression did not seem to impact the patient-reported outcomes from the phase III PACIFIC trial, which evaluated the use of durvalumab versus placebo in patients with unresectable stage III non–small cell lung cancer (NSCLC). In fact, Marina C. Garassino, MD, of the Fondazione IRCCS–Istituto Nazionale dei Tumori, Milan, Italy, and colleagues reported no clinically meaningful differences in patient-reported outcomes between the treatment arms across PD-L1 subgroups. Presenting these findings at the 2019 European Lung Cancer Conference (ELCC), Dr. Garassino said their results were similar to those in the intent-to-treat population.
The PACIFIC study, which involved 235 centers in 26 countries, focused on more than 700 patients with stage III NSCLC who experienced no disease progression after platinum-based concurrent chemoradiotherapy. They were randomly assigned to receive durvalumab (n = 473) or placebo (n = 236). The results of the study were retrospectively investigated for the impact of tumor PD-L1 expression on patient-reported outcomes. A clinically meaningful difference was defined as ≥ 10 points from baseline.
Patient-reported outcomes were stable from baseline across all 5 PD-L1 subgroups (tumor cell expression ≥ 25%, < 25%, ≥ 1%, < 1%, and unknown). However, both durvalumab and placebo treatments improved patient-reported outcomes for dysphagia and alopecia across most PD-L1 subgroups, similar to the intent-to-treat population. “Clinically meaningful improvements (decreases ≥ 10 points) from baseline to week 48 were observed for dysphagia and alopecia across most PD-L1 subgroups for both durvalumab and placebo,” the investigators noted.
Disclosure: The study authors’ disclosure information may be found at cslide.ctimeetingtech.com.
